Real-world osimertinib for EGFR mutation-positive non-small-cell lung cancer with acquired T790M mutation

被引：8

作者：

Imamura, Fumio ^{[1
]}

Kimura, Madoka ^{[1
]}

Yano, Yukihiro ^{[2
]}

Mori, Masahide ^{[2
]}

Suzuki, Hidekazu ^{[3
]}

Hirashima, Tomonori ^{[3
]}

Ihara, Shouichi ^{[4
]}

Komuta, Kiyoshi ^{[4
]}

Shiroyama, Takayuki ^{[5
]}

Nagatomo, Izumi ^{[5
]}

Kumagai, Toru ^{[1
]}

机构：

[1] Osaka Int Canc Inst, Dept Thorac Oncol, Chuo Ku, 3-1-69 Otemae, Osaka 5418567, Japan

[2] Natl Hosp Org Osaka Toneyama Med Ctr, Dept Thorac Oncol, 5-1-1 Toneyama, Toyonaka, Osaka 5608552, Japan

[3] Osaka Habikino Med Ctr, Dept Thorac Oncol, 3-7-1 Habikino, Habikino, Osaka 5838588, Japan

[4] Osaka Police Hosp, Dept Respirol, Tenoji Ku, 2-6-40 Karasugatsuji, Osaka 5438922, Japan

[5] Osaka Univ, Grad Sch Med, Dept Resp Med & Clin Immunol, 2-2 Yamadaoka, Suita, Osaka 5650871, Japan

来源：

FUTURE ONCOLOGY | 2020年 / 16卷 / 21期

关键词：

1ST-LINE TREATMENT; OPEN-LABEL; GEFITINIB;

D O I：

10.2217/fon-2020-0203

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Aim: Osimertinib is a key drug for EGFR mutation-positive non-small-cell lung cancer (NSCLC). As the hazards ratio of overall survival in comparison with first-generation EGFR-tyrosine kinase inhibitors was almost similar between FLAURA and ARCHER 1050, salvage use of osimertinib is still a treatment option. Patients & methods: We retrospectively analyzed the clinical courses of EGFR mutation-positive NSCLC patients who were potential candidates for salvage osimertinib. Results: Among 524 patients enrolled from five hospitals, 302 patients underwent biopsy, with 52.6% detection rate of T790M. Osimertinib was administered in 93.6% of the T790M-positive patients. The overall response rate and median progression-free survival time of osimertinib were calculated with 147 patients, to be 55.6% and 17.2 months, respectively. Conclusion: Osimertinib is active for T790M-driven acquired resistance in EGFR-mutant NSCLC, but the detection of T790M was unsatisfactory.

引用

页码：1537 / 1546

页数：10

共 50 条

[1] Osimertinib for EGFR T790M mutation-positive non-small cell lung cancer
Soejima, Kenzo
Yasuda, Hiroyuki
Hirano, Toshiyuki
[J]. EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2017, 10 (01) : 31 - 38
[2] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer and a poor performance status
Nakashima, Kazuhisa
Kimura, Madoka
Akamatsu, Hiroaki
Daga, Haruko
Imai, Hisao
Taira, Tetsuhiko
Ko, Ryo
Hisamatsu, Yasushi
Nishino, Kazumi
Sugimoto, Takeya
Miyashita, Yosuke
Takahashi, Toshiaki
Kumagai, Toru
Yamamoto, Nobuyuki
Murakami, Haruyasu
[J]. JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2019, 49 (07) : 671 - 675
[3] Osimertinib for the Treatment of Metastatic EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Khozin, Sean
Weinstock, Chana
Blumenthal, Gideon M.
Cheng, Joyce
He, Kun
Zhuang, Luning
Zhao, Hong
Charlab, Rosane
Fan, Ingrid
Keegan, Patricia
Pazdur, Richard
[J]. CLINICAL CANCER RESEARCH, 2017, 23 (09) : 2131 - 2135
[4] Targeting the Gatekeeper: Osimertinib in EGFR T790M Mutation-Positive Non-Small Cell Lung Cancer
Skoulidis, Ferdinandos
Papadimitrakopoulou, Vassiliki A.
[J]. CLINICAL CANCER RESEARCH, 2017, 23 (03) : 618 - 622
[5] The safety and efficacy of osimertinib for the treatment of EGFR T790M mutation positive non-small-cell lung cancer
Gao, Xin
Le, Xiuning
Costa, Daniel B.
[J]. EXPERT REVIEW OF ANTICANCER THERAPY, 2016, 16 (04) : 383 - 390
[6] Osimertinib for patients with EGFR T790M mutation-positive non-small-cell lung cancer who have poor performance status
Kimura, Madoka
Nishino, Kazumi
Imamura, Fumio
Nakashima, Kazuhisa
Takahashi, Toshiaki
Sugimoto, Takeya
Akamatsu, Hiroaki
Yamamoto, Nobuyuki
Daga, Haruko
Imai, Hisao
Taira, Tetsuhiko
Miyashita, Yosuke
Ko, Ryo
Hisamatsu, Yasushi
Murakami, Haruyasu
[J]. ANNALS OF ONCOLOGY, 2018, 29
[7] Efficacy, safety, and resistance profile of osimertinib in T790M mutation-positive non-small cell lung cancer in real-world practice
Oh, Dong Kyu
Ji, Won Jun
Kim, Woo Sung
Choi, Chang-Min
Yoon, Shin-Kyo
Rho, Jin Kyung
Lee, Jae Cheol
[J]. PLOS ONE, 2019, 14 (01):
[8] Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small-cell lung cancer: AURA3 trial
Akamatsu, Hiroaki
Katakami, Nobuyuki
Okamoto, Isamu
Kato, Terufumi
Kim, Young Hak
Imamura, Fumio
Shinkai, Masaharu
Hodge, Rachel A.
Uchida, Hirohiko
Hida, Toyoaki
[J]. CANCER SCIENCE, 2018, 109 (06): : 1930 - 1938
[9] Targeting the EGFR T790M mutation in non-small-cell lung cancer
Normanno, Nicola
Maiello, Monica Rosaria
Chicchinelli, Nicoletta
Iannaccone, Alessia
Esposito, Claudia
De Cecio, Rossella
D'alessio, Amelia
De Luca, Antonella
[J]. EXPERT OPINION ON THERAPEUTIC TARGETS, 2017, 21 (02) : 159 - 165
[10] ASTRIS China: A Real-world Study of Osimertinib in Patients with EGFR T790M Positive Non-small-cell Lung Cancer (NSCLC)
Zhou, Q.
Zhang, H. -L.
Jiang, L. -Y.
Shi, Y. -K.
Chen, Y.
Yu, J. -M.
Zhou, C. -C.
He, Y.
Hu, Y. -P.
Liang, Z. -A.
Pan, Y. -Y.
Zhuo, W. -L.
Song, Y.
Wu, G.
Chen, G. -Y.
Lu, Y.
Zhang, C. -Y.
Zhang, C. -Y.
Zhang, Y. -P.
Chen, Y.
Lu, S.
Wu, Y. -L.
[J]. JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S429 - S430

← 1 2 3 4 5 →